1.90 
0.01(0.26%) 3:59PM EDT
| Prev Close: | 1.90 |
|---|
| Open: | 1.88 |
|---|
| Bid: | N/A |
|---|
| Ask: | 2.25 x 100 |
|---|
| 1y Target Est: | 3.60 |
|---|
| Beta: | 2.86 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 1.86 - 1.91 |
|---|
| 52wk Range: | 1.70 - 5.64 |
|---|
| Volume: | 319,637 |
|---|
| Avg Vol (3m): | 245,202 |
|---|
| Market Cap: | 48.13M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.33 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Aeterna Zentaris announces dismissal of class action lawsuitat theflyonthewall.com(Thu, Jun 6)
- Aeterna Zentaris Announces Dismissal of Class Action LawsuitCNW Group(Thu, Jun 6)
- Aeterna Zentaris Announces Dismissal of Class Action LawsuitPR Newswire(Thu, Jun 6)
- Rexahn's Oncology Platform Led By Its Akt-1 Inhibitor Challenges Big Pharma With Ground-Breaking Cancer Therapyat Seeking Alpha(Wed, Jun 5)
- Aeterna Zentaris: Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin (AEZS-108) in Prostate Cancer Reported at ASCOCNW Group(Mon, Jun 3)
- Aeterna Zentaris: Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin (AEZS-108) in Prostate Cancer Reported at ASCOPR Newswire(Mon, Jun 3)
- Tackling Cancer: Your Best Investing Ideasat Motley Fool(Sun, Jun 2)
- BMRN's Vimizim Under ReviewZacks(Fri, May 31)
- Aeterna Zentaris: Posters to be Presented on Phase 1 and Phase 2 Trials with AEZS-108 in Prostate and Breast Cancer at Upcoming ASCO MeetingPR Newswire(Thu, May 23)
- Aeterna Zentaris: Posters to be Presented on Phase 1 and Phase 2 Trials with AEZS-108 in Prostate and Breast Cancer at Upcoming ASCO MeetingCNW Group(Thu, May 23)
- Aeterna Zentaris Announces "At-the-Market" Issuance ProgramCNW Group(Tue, May 21)
- Aeterna Zentaris Announces "At-the-Market" Issuance ProgramPR Newswire(Tue, May 21)
- Biotech Companies: The FDA Doesn't Care About Your Phase 3 Trialsat Motley Fool(Mon, May 20)
- Smaller Companies With Potential For Big Returnsat Seeking Alpha(Thu, May 16)
- Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in TorontoPR Newswire(Wed, May 15)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 1.18 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.65 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.21 |
|---|
| Mean Recommendation*: | 2.7 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Aeterna Zentaris Inc. a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for oncology and endocrine therapy primarily in Switzerland, the United States, and Japan.
View More